Erwinaze Lyophilisate For Solution For Injection 10000iu Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Erwinaze: Lyophilisate for solution for injection (10000IU)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

ASPARAGINASE ERWINIA CHRYSANTHEMI (er win e uh as PAR a jin ase) is used to treat acute lymphocytic leukemia (ALL). It is used in combination with other chemotherapy agents.

In-Depth Information

Erwinaze 10,000unit Powder for Injection

NDC: 579020249
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Acute Lymphocytic Leukemia (ALL)

Storage Information
Protect from light
Store unopened containers in refrigerator (36 to 46 degrees F)
Do not freeze
Erwinaze 10,000unit Powder for Injection

Reported Side Effects for Erwinaze 10,000unit Powder for Injection

Upset Stomach Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
Blood Clot Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Injection Site Reaction Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Elevated Hepatic Enzymes Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
Bleeding Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Stomach Pain Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
High Bilirubin Level Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
High Ammonia Levels Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Disseminated Intravascular Coagulation (DIC) Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Convulsions Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Headache Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Increased Blood Sugar Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Pancreas Incidence:
2.0-7.0%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
11.0-13.3%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Erwinaze

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5